Skip to main content

Advertisement

SpringerLink
Log in

Serum matrix metalloproteinase-7: a potential biomarker in patients with Lynch Syndrome

  • Original Article
  • Published:
Molecular Biology Reports Aims and scope Submit manuscript

Abstract

Background and aims

The expression of tissue and serum matrix metalloproteinase-7 (MMP-7) was shown to be elevated both in colon cancer and dysplastic lesions. We aimed to evaluate, for the first time, its role as a diagnostic marker in Lynch syndrome (LS) carriers, a hereditary syndrome with predisposition to colon cancer.

Methods

This was a case control study. Baseline serum MMP-7 levels were determined by ELISA in 40 colon cancer patients, 62 LS-carriers and 60 healthy controls. Retrieved data from medical files included demographics, background diseases, clinical data regarding tumor characteristics and genetic data. We assessed the association of serum MMP-7 levels with different variables in the study cohort using linear regression model adjusted for potential confounders.

Results

In crude analysis, serum MMP-7 levels were significantly higher in colon cancer group compared to LS-carriers and controls [median (IQR) 4.1 ng/ml (2.7–6.0), 2.3 ng/ml (1.7–3.1), 2.5 ng/ml (1.5–3.7), respectively; p value - p < 0.001) while there was no difference between the two last groups (p value = 0.583). However, after adjusting for age and gender, LS-carriers’ patients had 18% higher concentrations of serum MMP-7 compared to healthy controls (p value = 0.037), while colon cancer patients had 50% higher serum MMP-7 level in comparison to healthy controls (p value < 0.001). Additionally, age was positively associated with higher serum MMP-7 levels across all study groups (r = 0.67, p value < 0.001). In contrast, no correlation was observed between serum MMP-7 and either tumor staging and gene mutation.

Conclusions

Age-adjusted serum MMP-7 levels in asymptomatic LS carriers are higher than its levels in healthy population. While in colon cancer, MMP-7 higher level probably reflects the tumor burden and may have a prognostic effect, its significance and clinical applicability as a biomarker for tumorigenesis in LS is less clear and should be elucidated.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3

Similar content being viewed by others

Data availability

Not applicable.

References

  1. Lynch HT, Lynch PM, Lanspa SJ et al (2009) Review of the Lynch syndrome: history, molecular genetics, screening, differential diagnosis, and medico-legal ramifications. Clin Genet 76:1–18

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  2. Møller P, Seppälä TT, Bernstein I et al (2018) Cancer risk and survival in path MMR carriers by gene and gender up to 75 years of age: a report from the prospective Lynch Syndrome Database. Gut 67:1306–1316

    Article  PubMed  Google Scholar 

  3. Ahadova A, Seppälä TT, Engel C et al (2021) The “unnatural” history of colorectal cancer in Lynch syndrome: Lessons from colonoscopy surveillance. Int J Cancer 148:800–811

    Article  CAS  PubMed  Google Scholar 

  4. Ballhausen A, Przybilla MJ, Jendrusch M et al (2020) The shared frameshift mutation landscape of microsatellite-unstable cancers suggests immunoediting during tumor evolution. Nat Commun 11:4740

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  5. Bohaumilitzky L, Kluck K, Hüneburg R et al (2021) The different immune profiles of normal colonic mucosa in cancer-free lynch syndrome carriers and Lynch syndrome colorectal cancer patients. Gastroenterology. https://doi.org/10.1053/j.gastro.2021.11.029

    Article  PubMed  Google Scholar 

  6. Cui N, Hu M, Khalil RA (2017) Biochemical and biological attributes of matrix metalloproteinases. Prog Mol Biol Transl Sci 147:1–73

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Wang Q, Wang K, Tan X, Li Z, Wang H (2022) Immunomodulatory role of metalloproteases in cancers: current progress and future trends. Front Immunol 13:1064033

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  8. Alaseem A, Alhazzani K, Dondapati P et al (2019) Matrix Metalloproteinases: a challenging paradigm of cancer management. Semin Cancer Biol 56:100–115

    Article  CAS  PubMed  Google Scholar 

  9. Gonzalez-Avila G, Sommer B, Mendoza-Posada DA et al (2019) Matrix metalloproteinases participation in the metastatic process and their diagnostic and therapeutic applications in cancer. Crit Rev Oncol Hematol 137:57–83

    Article  PubMed  Google Scholar 

  10. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174

    Article  CAS  PubMed  Google Scholar 

  11. Ii M, Yamamoto H, Adachi Y et al (2006) Role of matrix metalloproteinase-7 (matrilysin) in human cancer invasion, apoptosis, growth and angiogenesis. Exp Biol Med 231:20–27

    Article  CAS  Google Scholar 

  12. Adachi Y, Yamamoto H, Itoh FY et al (1999) Contribution of matrilysin (MMP-7) to the metastatic pathway of human colorectal cancers. Gut 45:252–258

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. van der Jagt MF, Wobbes T, Strobbe LJ et al (2010) Metalloproteinases and their regulators in colorectal cancer. J Surg Oncol 101:259–269

    Article  PubMed  Google Scholar 

  14. Masaki T, Matsuoka H, Sugiyama M et al (2001) Matrilysin (MMP-7) as a significant determinant of malignant potential of early invasive colorectal carcinomas. Br J Cancer 84:1317–1321

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Sun DW, Zhang YY, Qi Y et al (2015) Prognostic significance of MMP-7 expression in colorectal cancer: a meta-analysis. Cancer Epidemiol 39:135–142

    Article  PubMed  Google Scholar 

  16. Xing XJ, Gu XH, Ma TF (2014) Relationship of serum MMP-7 levels for colorectal cancer: a meta-analysis. Tumour Biol 35:10515–10522

    Article  CAS  PubMed  Google Scholar 

  17. Maurel J, Nadal C, Garcia-Albeniz X et al (2007) Serum matrix metalloproteinase 7 levels identifies poor prognosis advanced colorectal cancer patients. Int J Cancer 121:1066–1071

    Article  CAS  PubMed  Google Scholar 

  18. Klupp F, Neumann L, Kahlert C et al (2016) Serum MMP-7, MMP10 and MMP12 level as negative prognostic markers in colon cancer patients. BMC Cancer 16:494

    Article  PubMed  PubMed Central  Google Scholar 

  19. McDonnell S, Navre M, Coffey R et al (1991) Expression and localization of the matrix metalloproteinase pump-1 (MMP-7) in human gastric and colon carcinoma. Mol Carcinog 4:527–533

    Article  CAS  PubMed  Google Scholar 

  20. Qasim BJ, Ali HH, Hussein AG (2013) Immunohistochemical expression of matrix metalloproteinase-7 in human colorectal adenomas using specified automated cellular image analysis system: a clinicopathological study. Saudi J Gastroenterol 19:23–27

    Article  PubMed  PubMed Central  Google Scholar 

  21. He L, Kang Q, Chan KI et al (2023) The immunomodulatory role of matrix metalloproteinases in colitis-associated cancer. Front Immunol 13:1093990

    Article  PubMed  PubMed Central  Google Scholar 

  22. Pezeshkian Z, Forouzesh F, Peyravian N et al (2017) Clinicopathological correlations of VEGF-A and MMP-7 genes expression in different types of colorectal adenoma polyps. WCRJ 4:e978

    Google Scholar 

  23. Polistena A, Cucina A, Dinicola S et al (2014) MMP-7 expression in colorectal tumours of different stages. In vivo 28:105–110

    CAS  PubMed  Google Scholar 

  24. Pezeshkian Z, Nobili S, Peyravian N et al (2021) Insights into the role of Matrix Metalloproteinases in Precancerous Conditions and in Colorectal Cancer. Cancers (Basel) 13:6226

    Article  CAS  PubMed  Google Scholar 

  25. Gu E, Zhu GL, Wei XQ (2014) Pithelial-mesenchymal transition in colorectal cancer tissue of patients with Lynch syndrome. World J Gastroenterol 20:250–257

    Article  PubMed  PubMed Central  Google Scholar 

  26. Goldberg Y, Kedar I, KarIiv R et al (2014) Lynch Syndrome in high risk Ashkenazi Jews in Israel. Fam Cancer 13:65–73

    Article  PubMed  Google Scholar 

  27. Huachuan Z, Xiaohan L, Jinmin S et al (2003) Expression of matrix metalloproteinase-7 involving in growth, invasion, metastasis and angiogenesis of gastric cancer. Chin Med Sci J 18:80–86

    PubMed  Google Scholar 

  28. Garalla HM, Lertkowit N, Tiszlavicz LZ et al (2018) Matrix metalloproteinase (MMP)-7 in Barrett’s esophagus and esophageal adenocarcinoma: expression, metabolism, and functional significance. Physiol Rep 6:e13683

    Article  PubMed  PubMed Central  Google Scholar 

  29. Zhang H, Wang Y, Chen T et al (2019) Aberrant activation of hedgehog signalling promotes Cell Migration and Invasion Via Matrix Metalloproteinase-7 in ovarian Cancer cells. J Cancer 10(4):990–1003

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Szarvas T, Becker M, vom Dorp F et al (2010) Matrix metalloproteinase-7 as a marker of metastasis and predictor of poor survival in bladder cancer. Cancer Sci 101:1300–1308

    Article  CAS  PubMed  Google Scholar 

  31. Bohaumilitzky L, Kluck K, Hüneburg R et al (2021) The different immune profiles of normal colonic mucosa in cancer-free lynch syndrome carriers and Lynch syndrome colorectal cancer patients. Gastroenterology. https://doi.org/10.1053/j.gastro.2021.11.029

    Article  PubMed  Google Scholar 

  32. Kloor M, von Doeberitz K (2016) The immune biology of microsatellite unstable cancer. Trends Cancer 2:121–131

    Article  PubMed  Google Scholar 

  33. Barabás L, Hritz I, István G et al (2021) The behavior of MMP-2, MMP-7, MMP-9, and their inhibitors TIMP-1 and TIMP-2 in Adenoma-Colorectal Cancer sequence. Dig Dis 39:217–224

    Article  PubMed  Google Scholar 

  34. Strand S, Vollmer P, van den Abeelen L et al (2004) Cleavage of CD95 by matrix metalloproteinase-7 induces apoptosis resistance in tumour cells. Oncogene 23(20):3732–3736

    Article  CAS  PubMed  Google Scholar 

  35. Murphy G (2011) Tissue inhibitors of metalloproteinases. Genome Biol 12:233

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  36. Abba M, Patil N, Allgayer H (2014) MicroRNAs in the regulation of MMPs and metastasis. Cancers 6:625–645

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  37. Yu B, Liu X, Chang H (2017) MicroRNA-143 inhibits colorectal cancer cell proliferation by targeting MMP-7. Minerva Med 108:13–19

    Article  PubMed  Google Scholar 

  38. Bonnema DD, Webb CS, Pennington WR et al (2007) Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J Card Fail 13:530–540

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  39. Grzechocińska B, Dąbrowski FA, Sierdzinski J et al (2019) The association between serum metalloproteinase concentration, obesity, and hormone levels in reproductive-aged women. Endokrynol Pol 70(1):49–56

    Article  PubMed  Google Scholar 

  40. Yilmaz Y, Eren F (2019) Serum biomarkers of fibrosis and extracellular matrix remodeling in patients with nonalcoholic fatty liver disease: association with liver histology. Eur J Gastroenterol Hepatol 31(1):43–46

    Article  CAS  PubMed  Google Scholar 

  41. Kadoglou NP, Sailer N, Fotiadis G et al (2014) The impact of type 2 diabetes and atorvastatin treatment on serum levels of MMP-7 and MMP-8. Exp Clin Endocrinol Diabetes 122(1):44–49

    Article  CAS  PubMed  Google Scholar 

  42. Hsieh FI, Chiou HY, Hu CJ et al (2019) Combined effects of MMP-7, MMP-8 and MMP-26 on the risk of ischemic stroke. J Clin Med 18(11):2011

    Article  Google Scholar 

  43. Mossa AH, Cammisotto PG, Shamout S et al (2021) Imbalance of nerve growth factor metabolism in aging women with overactive bladder syndrome. World J Urol 39(6):2055–2063

    Article  CAS  PubMed  Google Scholar 

  44. Tao Y, Qiu X, Xu C et al (2015) Expression and correlation of matrix metalloproteinase-7 and interleukin-15 in human osteoarthritis. Int J Clin Exp Pathol 8(8):9112–9118

    PubMed  PubMed Central  Google Scholar 

Download references

Funding

This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.

Author information

Authors and Affiliations

  1. Institute of Gastroenterology, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

    Doron Yablecovitch, Hussein Mahajna, Orit Picard, Miri Yavzori, Ella Fudim, Shomron Ben-Horin & Ido Laish

  2. Department of Surgery and Transplantations B/C, Chaim Sheba Medical Center, Tel Hashomer, Ramat Gan, Israel

    Nir Horesh & Efraim Katz

  3. Shalvata Mental Health Center, Hod Hasharon, Israel

    Talia Saker

  4. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel

    Doron Yablecovitch, Hussein Mahajna, Nir Horesh, Efraim Katz, Orit Picard, Miri Yavzori, Ella Fudim, Talia Saker, Shomron Ben-Horin & Ido Laish

Authors
  1. Doron Yablecovitch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Hussein Mahajna
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Nir Horesh
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Efraim Katz
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Orit Picard
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Miri Yavzori
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Ella Fudim
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Talia Saker
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Shomron Ben-Horin
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Ido Laish
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Doron Yablecovitch.

Ethics declarations

Competing interests

The Authors declare that there is no conflict of interest.

Ethical approval

This study was conducted in accordance with the Declaration of Helsinki and the ethical approval for this study was exempted by the Medical Ethics Committee of the Sheba Medical Center.

Consent to participants

All patients signed an informed consent.

Consent for publication

Not applicable.

Additional information

Publisher’s Note

Springer nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Yablecovitch, D., Mahajna, H., Horesh, N. et al. Serum matrix metalloproteinase-7: a potential biomarker in patients with Lynch Syndrome. Mol Biol Rep 50, 7471–7477 (2023). https://doi.org/10.1007/s11033-023-08614-y

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11033-023-08614-y

Keywords

Search

Navigation